0.1678

10.77% -0.0188

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $0.1678, with a volume of 2.83M. It is down -10.77% in the last 24 hours and down -64.67% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$0.1866

Open:

$0.194

24h Volume:

2.83M

Relative Volume:

1.69

Market Cap:

$9.26M

Revenue:

$1.38M

Net Income/Loss:

$-179.05M

P/E Ratio:

-0.0273

EPS:

-6.14

Net Cash Flow:

$-155.03M

1W Performance:

-48.93%

1M Performance:

-64.67%

6M Performance:

-81.73%

1Y Performance:

-95.60%

1-Day Range:

$0.16

$0.1948

1-Week Range:

$0.16

$0.33

52-Week Range:

$0.16

$3.82

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2024-11-12

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	0.1674	9.26M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	473.85	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.27	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	651.13	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.65	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.63	28.75B	3.30B	-501.07M	1.03B	-2.1146

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

09:56 AM

BioXcel Therapeutics announces reverse stock split - Hartford Business Journal

09:56 AM

12:39 PM

BioXcel Therapeutics announces 1-for-16 reverse stock split By Investing.com - Investing.com Nigeria

12:39 PM

Feb 06, 2025

BioXcel to Implement Reverse Stock Split; Shares Fall -February 06, 2025 at 01:28 pm EST - Marketscreener.com

Feb 06, 2025

BioXcel Therapeutics enacts 1-for-16 reverse stock split By Investing.com - Investing.com UK

Feb 06, 2025

BioXcel Therapeutics Announces Reverse Stock Split - The Manila Times

Feb 06, 2025

BioXcel's Strategic Reverse Split: Critical Move to Preserve Nasdaq StatusWhat's at Stake - StockTitan

Feb 06, 2025

Feb 05, 2025

BioXcel Therapeutics advances key clinical trials - Investing.com India

Feb 05, 2025